Two new consultations have been opened on the GMMMG site; see details below. Both consultations will run until 5pm on Monday 1st August 2022. Comments can be submitted using the feedback forms on the GMMMG consultations page, and comments are invited from all stakeholders.
CRG seek comments from Greater Manchester on this position statement regarding the prescribing of best value direct oral anticoagulants (DOACs) for stroke prevention in atrial fibrillation. When developing the statement CRG carefully considered, amongst other things:
- The financial savings associated with increased edoxaban use,
- A clinician’s freedom to prescribe the treatment they think is most appropriate for their patient
- The available evidence base to support (or not) the use of one medicine over another.
- The Investment and Impact Fund indicators
- The high court ruling that has invalidated the patent for apixaban, and may yet be subject to appeal.
CRG want edoxaban to be the first choice DOAC for use in non-valvular AF, and an alternative used where edoxaban would not be safe or appropriate. This position is still current at the time of publication of the draft statement, despite the legal issues surrounding apixaban.
GMMMG therefore seek feedback from a wide range of stakeholders regarding this statement.
CRG seek comments from Greater Manchester on this draft pathway for the management of hypersalivation. It has been developed and approved by MFT and CRG are seeking to adapt it for use across GM, particularly in primary care.
It looks to provide evidence-based, cost-effective recommendations on the management of hypersalivation in a number of conditions.
GMMMG therefore seek feedback from a wide range of stakeholders regarding this pathway